Poland· PL-100327850

Etoposide Kabi

A etoposide product containing etoposidum, registered in Poland by Fresenius Kabi Polska Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.

ATC L01CB01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedEtoposide KabiATCL01CB01REGISTER NO.PL-100327850PACKS LISTED4CHECKEDJune 7, 2026

Where it is registered

Etoposide is registered in 17 of 19 countries.

Countries holding a registration under ATC L01CB01 (etoposide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Etoposide · ATC L01CB01

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of etoposide costs, country by country.

Normalised to the WHO defined daily dose (50 mg), the median price runs from $9.95 in France to $18.65 in Switzerland — a ×1.9 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Etoposide · price per daily dose (50 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$18.65
  • FR France$9.95
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Etoposidum
Manufacturer
Fresenius Kabi Polska Sp. z o.o.
Country
Poland (PL)
ATC code
L01CB01
ATC class
Etoposide
Defined daily dose
50 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
June 7, 2026

Packs & prices · 4

  • gtin
    05909991196455
  • gtin
    05909991196462
  • gtin
    05909991196479
  • gtin
    05909991196486

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

576 interactions on record for etoposide.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Etoposide · interactions on record

576 records

  • 30 severe
  • 290 moderate
  • 21 minor
  • 235 info

Most severe, free to view

  • CladribineL01BB04severe
  • AprepitantA04AD12moderate
  • RolapitantA04AD14moderate
  • EliglustatA16AX10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Etoposide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All etoposide products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Etoposid Accord, Etoposid Ebewe
  • Belgium · Celltop, Eposin
  • Bulgaria · Eтопозид Акорд
  • Cyprus · Etoposide Accord
  • Czechia · Etoposid Ebewe, Etoposide Accord
  • Germany · Eto-Cell, Eto-Cell®
  • Denmark · Etoposid Accord, Etoposid Ebewe
  • Estonia · Etoposide Accord, Etoposide Kabi
  • Spain · Etopósido Accord, Etopósido Hikma
  • Finland · Etoposid Fresenius Kabi, Etoposide Accord
  • France · Celltop, Etopophos
  • United Kingdom (Northern Ireland) · Etopophos, Etoposide
  • Greece · Etobion
  • Croatia · Etoposide Sandoz
  • Hungary · Etoposid Sandoz, Etoposide Accord
  • Ireland · Etoposide, Etoposide Accord Healthcare
  • Iceland · Etópósíð Accord
  • Italy · Etoposide Accord, Etoposide Hikma
  • Lithuania · Etoposid Ebewe, Etoposide Accord
  • Luxembourg · Eposin, Etoposide Accord Healthcare
  • Latvia · Etoposide Accord, Etoposide Ebewe
  • Netherlands · Eposin, Etoposide Accord
  • Norway · Etoposid Ebewe, Etoposid Fresenius Kabi
  • Portugal · Etoposido Accord, Etoposido Hikma
  • Romania · Etoposid Accord, Etoposide Teva
  • Sweden · Eposin, Etopofos
  • Slovenia · Ebeposid, Eposin
  • Slovakia · Etoposid Sandoz, Etopozid Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/72008736-46a2-486f-93ee-d9e8502c92c0
GET /v1/drugs/72008736-46a2-486f-93ee-d9e8502c92c0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "20 mg/ml",
  "packaging": "05909991196455 ¦ Rp ¦ 104971\n1 fiol. 10 ml\n05909991196462 ¦ Rp ¦ 104972\n1 fiol. 5 ml\n05909991196479 ¦ Rp ¦ 104973\n1 fiol. 50 ml\n05909991196486 ¦ Rp ¦ 104974\n1 fiol. 25 ml",
  "substance": "Etoposidum 20 mg/ml",
  "common_name": "Etoposidum",
  "pl_product_id": "100327850",
  "pozwolenie_nr": "22151",
  "auth_procedure": "DCP",
  "authorisation_validity": "2023-06-13"
}

See everything about etoposide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.